Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 3/20 | 0.60 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8007000 | 0.88 | HCRTR1 (0.47) | HCRTR2HCRTR1OPRK1PRMT5 | |
| SCHEMBL9928401 | 0.88 | HCRTR1 (0.51) | HCRTR2HCRTR1OPRK1PRMT5 | |
| SCHEMBL1119975 | 0.86 | HCRTR1 (0.49) | HCRTR2HCRTR1OPRK1 | |
| SCHEMBL1598674 | 0.86 | FPR3 (0.53) | HCRTR2HCRTR1OPRK1RAB9ANPC1 | |
| SCHEMBL1598677 | 0.86 | FPR3 (0.53) | HCRTR2HCRTR1OPRK1RAB9ANPC1 | |
| SCHEMBL4303727 | 0.85 | HCRTR2 (0.64) | HCRTR2HCRTR1OPRK1POLBRAB9A | |
| SCHEMBL12846343 | 0.85 | HCRTR2 (0.62) | HCRTR2HCRTR1OPRK1POLBRAB9A | |
| SCHEMBL9928406 | 0.79 | HCRTR1 (0.42) | HCRTR2HCRTR1OPRK1PRMT5KMT2A | |
| SCHEMBL6519220 | 0.78 | HCRTR1 (0.71) | HCRTR2HCRTR1OPRK1RAB9ANPC1 | |
| SCHEMBL1119830 | 0.78 | HCRTR2 (0.75) | HCRTR2HCRTR1OPRK1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2009124956-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | HCRTR2, HCRTR1, NPY4R | HCRTR2 1/4885HCRTR1 2/4885OPRK1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.